$BLLN

Tsao David sold $2.5M of BLLN

Tsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $124.88 ($122.84–$126.90, $2.50M total) across 10 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tsao David
Published Jul 15, 2026, 8:38 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The main tradable element is the disclosed insider selling amount and the fact it was pre-arranged under Rule 10b5-1, which generally reduces interpretive weight.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a major repricing without accompanying fundamental news.

03

What to watch

The filing does not disclose any new company-specific operational or financial information; traders should avoid extrapolating fundamentals from one insider transaction.

Relevance 5/10Novelty 5/10Timing: Filed on 2026-07-15 after the 2026-07-13 insider sale execution.

Background

This is an SEC Form 4 insider transaction by BillionToOne CTO Tsao David, executed across 10 trades on 2026-07-13 and reported on 2026-07-15.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne CTO Tsao David sold about $2.50M of BLLN shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any move would be small and sentiment-driven.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 plan and a single insider sale, which typically has less signaling value than discretionary selling.

Market effects

No clear sector read-through from a single 10b5-1 insider sale at one biotech/diagnostics issuer.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so the market may ignore it.

Key entities

  • BillionToOne, Inc.

    Company whose insider sale is disclosed on Form 4.

  • Tsao David

    Chief Technology Officer and reporting insider who sold shares.

Related articles

$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.